Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017

FDA: No Harm in MRI Gadolinium Retention in the Brain

Gadolinium-based Contrast Agents for Magnetic Resonance Imaging (MRI): Drug Safety Communication - No Harmful Effects Identified With Brain Retention

FDA says gadolinium retention in the brain is not a safety issue

May 25, 2017 — A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for magnetic resonance imaging (MRI) has not identified adverse health effects from gadolinium retained in the brain. The FDA released a drug safety communication regarding all gadolinium-based contrast agents (GBCAs) earlier this week. 

The FDA said GBCAs may be associated with some gadolinium retention in the brain and other body tissues. However, the FDA said there is no evidence to date that gadolinium retention in the brain from any of the GBCAs is harmful. The agency said this includes GBCAs associated with higher retention of gadolinium. These findings prompted the the FDA say restricting GBCA use is not warranted at this time. FDA said it will continue to assess the safety of GBCAs and plan to have a public meeting to discuss this issue in the future.

The agency said it evaluated scientific publications and adverse event reports submitted to FDA. Some human and animal studies looked at GBCA use over periods longer than a year. These publications and reports show that gadolinium is retained in organs such as the brain, bones and skin. The publications show that linear GBCAs retain more gadolinium in the brain than macrocyclic GBCAs. However, the review did not identify adverse health effects related to this brain retention.

FDA continues to assess the safety of GBCAs. FDA’s National Center for Toxicological Research is conducting a study on brain retention of GBCAs in rats. Other research is also being conducted about how gadolinium is retained in the body. FDA will update the public when new information becomes available and we plan to have a public meeting to discuss this issue in the future.

The intravenous gadolinium contrast media specifically mentioned in the safety communication includes:
• Ablavar (gadofosveset trisodium) 
• Dotarem (gadoterate meglumine) 
• Eovist (gadoxetate disodium) 
• Gadavist (gadobutrol) 
• Magnevist (gadopentetate dimeglumine) 
• MultiHance (gadobenate dimeglumine) 
• Omniscan (gadodiamide) 
• OptiMARK (gadoversetamide) 
• ProHance (gadoteridol)

The FDA recommendations for healthcare professionals and patients remains unchanged from July 2015, when FDA first informed the public that FDA was investigating this potential risk with GBCAs. 

The agency said the agents should be used as is appropriate when considering the use of any medical imaging agent. It also stated healthcare professionals should limit GBCA use to circumstances in which additional information provided by the contrast agent is necessary and to assess the necessity of repetitive MRIs with GBCAs. 

The FDA said retention of gadolinium affects only GBCAs and does not apply to other types of scanning agents used for other imaging procedures, including iodine-based contrast used in X-ray and computed tomography (CT) imaging or radioisotopes used in PET or SPECT nuclear imaging.

Watch the VIDEO “MRI Gadolinium Contrast Retention in the Brain.” This is an interview with Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pittsburgh Medical Center, at RSNA 2016. He was involved in the key studies regarding gadolinium retention in the brain.

Read the article Gadolinium May Remain in Brain After Contrast MRI

Read the article MRIs During Pregnancy Are Safe, But Gadolinium Scans May Increase Risk to Fetus

 

For more information: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm559709.htm

Related Content

Arterys collaborated with GE Healthcare to create the ViosWorks software to cardiac MRI analysis.

Arterys collaborated with GE Healthcare to create the ViosWorks software. The software integrates artificial intelligence to speed workflow and perform a full 3-D chest volume scan with myocardium motion, blood flow, time and fully automated quantification.

Feature | Cardiac Imaging | March 30, 2018 | Jeff Zagoudis
Magnetic resonance imaging (MRI) for cardiac assessment provides a radiation-free alternative to other commonly used
New Policy Decisions Give Millions Access to HeartFlow FFRct Analysis
News | Cardiac Imaging | February 01, 2018
February 1, 2018 – HeartFlow announced that seven new commercial payers issued positive medical policies covering the
Clear detail of the in-stent restenosis can be seen in this image from the new high-resolution Canon Precision CT system. RSNA 2017, #RSNA2017, #RSNA17

Clear detail of the in-stent restenosis can be seen in this image from the new high-resolution Canon Aquilion Precision CT system.

Feature | Cardiac Imaging | January 23, 2018 | Dave Fornell
Medical imaging plays a key role in cardiology, and most of the newest radiology technology advances are first unveil
Philips Introduces Technology Maximizer Program for Imaging Equipment Upgrades
Technology | Cardiac Imaging | January 17, 2018
Philips recently announced the launch of Technology Maximizer, a cross-modality program designed to boost the clinical...
Videos | Cardiac Imaging | December 29, 2017
ITN and DAIC Editor Dave Fornell takes a tour of some of the most interesting new medical imaging technologies on the
Siemens Healthineers Introduces Share360 Tailored Service Portfolio
News | Cardiac Imaging | November 10, 2017
To address the specific needs of medical imaging clinical engineering departments nationwide, Siemens Healthineers has...
HeartFlow's FFR-CT (FFRct) analysis software can create a virtual FFR to assess coronary artery disease.

HeartFlow's FFR-CT analysis software uses a computed tomography scan and supercomputing fluid dynamics software to create a noninvasive, virtual FFR map of the entire coronary artery tree to determine the flow-limiting severity of ant lesions. 

News | Cardiac Imaging | November 06, 2017
November 6, 2017 – The Centers for Medicare & Medicaid Services (CMS) has finalized a New Technology Ambulatory P
Philips Announces Findings of Patient Experience in Imaging Research
News | Cardiac Imaging | October 24, 2017
Philips recently announced the key findings of its research focused on the patient experience in diagnostic imaging...
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of...
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Cardiac Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Overlay Init